Mirococept (APT070) is a complement inhibitor currently under development for treatment of rheumatoid arthritis and I/RI. It is a truncated form of the human Complement Receptor 1 (CR1) linked to... It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation.
- Mechanism
- Curator reviewed
Mirococept comprises the C3/C5 convertase-inhibiting region of CR1. This complement inhibitory domains of CR1 (in APT070) contain C3b-binding sites that lead to dissociation and inactivation of C3b from the classical and alternative pathway convertases. Mirococept effectively blocks and reduces the generation of the activated form of C3, and thwarts the release of both C3a and C5a.
- Primary indication
- Investigated for use/treatment in transplant (rejection), kidney disease, and rheumatoid arthritis.Curator reviewed
- Also known as
- myristoylated recombinant SCR1-3 of human complement reseptor type I
- Code names
- APT-070
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Mirococept, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account